莱菔硫烷对链脲佐霉素诱导的大鼠糖尿病白内障的治疗作用  

Effects of sulforaphane on streptozotocin-diabetic cataract of rats

作　　者：吴恺[1] 谭钢[1] 邵毅[2] 

机构地区：[1]南华大学附属第一医院眼科,湖南省衡阳市421001 [2]南昌大学第一附属医院眼科,江西省南昌市330006

出　　处：《眼科新进展》2016年第12期1105-1109,共5页Recent Advances in Ophthalmology

基　　金：国家自然科学基金资助(编号:81400372;81660158);江西省自然科学基金重大项目(编号:20161ACB21017);江西省青年科学基金(编号:20151BAB215016);江西省科技支撑计划项目(编号:20151BBG70223);衡阳市科技局科研课题(编号:2010KJ30)~~

摘　　要：目的探讨莱菔硫烷（Sulforaphane，SFN）对链脲佐霉素诱导的大鼠糖尿病白内障的治疗作用。方法将72只雄性sD大鼠随机分为正常对照组、模型组、SFN低剂量干预组、SFN中剂量干预组、SFN高剂量干预组和苄达赖氨酸（bendazacly-sine，BDL）组，每组12只，后5组腹腔一次性注射链脲佐菌素（65mg·kg^-1）建立糖尿病白内障模型，从造模成功当日开始，SFN低、中、高剂量干预组分别给予50mg·kg^-1、100mg·kg^-1、200mg·kg^-1 SFN灌胃，BDL组以200mg·kg^-1BDL灌胃，其余2组用同体积的生理盐水，每天1次，治疗12周后，测定空腹血糖水平，裂隙灯观察大鼠晶状体变化并对其混浊度进行分级，分离晶状体并制备成匀浆液，测定丙二醛（malondialdehyde，MDA）含量及超氧化物歧化酶（superoxide dismutase，SOD）、谷胱甘肽过氧化物酶（glutathione-peroxidase，GSH-Px）、过氧化氢酶（catalase，CAT）活性，EuSA检测糖基化终末产物（advanced glycosylation end products，AGEs）含量，行Western-blotting检测醛糖还原酶（aldose reductase，AR）表达。结果用药后12周，SFN中、高剂量干预组大鼠空腹血糖明显低于模型组（均为P〈0．05），而SFN低剂量干预组、BDL组仍处于高血糖水平，与模型组比较，差异均无统计学意义（均为P〉0．05）。正常对照组大鼠晶状体透明，无混浊发生；而模型组大鼠晶状体出现雾状混浊、核混浊，分级为Ⅲ-Ⅴ级，其混浊度显著高于正常对照组（P〈0．01）。与模型组比较，SFN中、高剂量干预组晶状体混浊度等级差异明显减轻（均为P〈0．05），而SFN低剂量干预组、BDL组晶状体混浊度等级与模型组相比，差异均无统计学意义（均为P〉0．05）。与正常对照组比较，模型组大鼠晶状体组织中MDA含量升高，而SOD、GSH-Px、CAT活性降低，差异均有统计学意义（均为P〈0．01）。经中、高剂量SFN或BDL处Objective To observe the effects of sulforaphane （SFN） on strepto- zotocin （STZ） -induced diabetic cataract of rats, and explore its related mechanisms. Methods Seventy-two male SD rats were randomly divided into normal control group, model group, SFN low-dose intervention group, SFN middle-dose intervention group, SFN high-dose intervention group, and bendazac lysine （BDL） group, 12 rats in each group. Rats in the latter 5 groups were intraperitoneally injected with STZ （65 mg·kg^-1 ） to establish diabetic cataract model. From the day of model establishment, rats in SFN low-, middle- and high-dose intervention groups were intragastrically treated with 50 mg·kg^-1 , 100 mg·kg^-1 and 200 mg·kg^-1 SFN, respectively. Rats in BDL group were intragastrically administrated with 200 mg·kg^-1 BDL. However, rats in nor- mal control and model groups were treated with the same volume of normal saline. Af- ter 12 weeks of drug treatment, fasting blood glucose was examined among groups. Eyes of rats were examined with slit lamp microscope on dilated pupils. Initiation and pro- gression of lenticular opacity were assessed according to the Azuma system. The lens were removed and prepared to homogenate. Subsequently, the content of malondialde- hyde （MDA） as well as the activities of superoxide dismutase （SOD）, glutathione-per- oxidase （GSH-Px） and catalase （CAT） were detected. Advanced glycosylation end products （AGEs） amount was measured using enzyme linked immunosorbent assay （ELISA）. In addition ,Western blotting was used to examine aldose reductase （AR） ex- pression. Results At 12 weeks after drug treatment, fasting blood glucose were signif- icantly decreased in the SFN middle- and high-dose intervention groups compared with the model group （ all P 〈 0.05 ）, but there was no statistical difference in the SFN low- dose intervention group and BDL group compared with the model group （ all P 〉 0.05 ）. The lens in the normal control group were clear without opacificat

关 键 词：莱菔硫烷 糖尿病白内障 氧化应激 糖基化终产物 醛糖还原酶 

分 类 号：R776.1[医药卫生—眼科]